NEUROGT INC
Durham, NC · Biotech · Private
Antibody cleaver (AbC) protein therapeutic that depletes anti-AAV antibodies to enable AAV gene therapy in seropositive patients
- Grants
- $7.9M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of gene therapy product for treating MPS IIIB | $397,823 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of gene therapy product for treating MPS IIIB | $284,425 | |
| Federal grant | Department of Health and Human Services · Phase I · Develop AAV9 gene replacement therapy for treating MPS I | $378,882 | |
| Federal grant | Department of Health and Human Services · Phase II · Protein depleting pre-existing antibodies for viral gene therapy | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Protein depleting pre-existing antibodies for viral gene therapy | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Develop AAV9 gene replacement therapy for treating MPS I | $323,802 | |
| Federal grant | Department of Health and Human Services · Phase II · Protein depleting pre-existing antibodies for viral gene therapy | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of gene therapy product for treating MPS IIIB | $456,414 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC | $349,909 | |
| Federal grant | Department of Health and Human Services · Phase II · Protein depleting pre-existing antibodies for viral gene therapy | $969,817 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of gene therapy product for treating MPS IIIB | $1,305,826 | |
| Federal grant | Department of Health and Human Services · Phase II · Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I | $1,499,504 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC | $342,740 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1709 | MTI BIOTECH, INC. | — | — |
| 1710 | GISMO THERAPEUTICS INC. | — | — |
| 1711 | SINOPIA BIOSCIENCES INC | — | — |
| 1712 | NEUROGT INC | — | — |
| 1713 | Lila Sciences | — | — |
| 1714 | ARC Biotechnology LLC | — | — |
| 1715 | ARMAGEN TECHNOLOGIES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.